Equities

ProQR Therapeutics NV

ProQR Therapeutics NV

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)1.76
  • Today's Change-0.03 / -1.68%
  • Shares traded198.20k
  • 1 Year change+0.57%
  • Beta0.4294
Data delayed at least 15 minutes, as of Jun 14 2024 21:00 BST.
More ▼
Improved Notifications for Markets Data Alerts
Improved Notifications for Markets Data Alerts
Want push notifications sent directly to your devices for equity price changes and breaking news stories? Let us know here.
 
Existing alertsView our existing alerts
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

ProQR Therapeutics N.V. is a pre-clinical stage biopharmaceutical company based in the Netherlands. The Company is engaged in the discovery and development of ribonucleic Acid (RNA)-based therapeutics for the treatment of severe genetic disorders. It designs its therapeutic candidates to specifically target and repair the defective messenger RNA, or Messenger Ribonucleic Acid (mRNA), that is transcribed from a mutated gene in order to restore the expression and function of normal, or wild-type protein. Its product candidates include QR-010, an RNA-based oligonucleotide for the treatment of cystic fibrosis (CF), QR-110, an oligonucleotide and for the treatment of Leber’s congenital amaurosis (LCA).

  • Revenue in USD (TTM)14.43m
  • Net income in USD-28.72m
  • Incorporated2012
  • Employees157.00
  • Location
    ProQR Therapeutics NVZernikedreef 9LEIDEN 2333 CKNetherlandsNLD
  • Phone+31 854894932
  • Websitehttps://www.proqr.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Conduit Pharmaceuticals Inc0.00-2.42m132.89m7.00---------0.0339-0.03390.00-0.0420.00----0.00-97.97-----------------25.68--------89.05------
CytoDyn Inc0.00-51.69m133.21m12.00---------0.055-0.0550.00-0.12060.00----0.00-414.98-259.98-----------235,303.80---0.88-----100.00--62.14------
Tevogen Bio Holdings Inc0.00-67.33k137.38m17.00---------0.0004-0.00040.00-0.0045------0.00-------------------8.191.74------99.69------
FitLife Brands Inc58.51m7.30m137.40m37.0020.204.6818.542.351.481.4811.876.391.203.8727.131,581,351.0015.0326.4019.3733.9241.5542.0912.4817.650.517712.320.3582--82.9725.2819.5867.31----
Global Pharmatech Inc.3.18m-2.24m138.32m217.00--1.02--43.51-0.0964-0.09640.13670.34280.22921.593.5714,649.77-16.44---22.55--46.21---71.75--1.62-9.870.2223--32.43---142.03------
Mediwound Ltd19.85m-12.75m139.07m100.00--6.13--7.01-1.38-1.382.152.440.3035.645.07198,510.00-19.46-24.48-25.65-32.9216.9243.27-64.24-38.431.83--0.218---29.4840.6065.73--64.66--
ProQR Therapeutics NV14.43m-28.72m142.72m157.00--3.97--9.89-0.3538-0.35380.17780.44230.0957----91,924.53-18.83-35.51-23.01-40.51-----196.75-926.31----0.3557--118.5110.5856.35--34.45--
G1 Therapeutics Inc84.04m-30.59m145.34m100.00--5.23--1.73-0.6146-0.61461.550.5310.63670.48526.07840,410.00-23.18-47.06-30.95-52.6491.89---36.40-268.592.55-3.310.6084--60.84--67.49------
Boundless Bio Inc-100.00bn-100.00bn145.99m72.00--------------4.79----------------------------0.00-------7.70------
Context Therapeutics Inc0.00-21.32m147.00m5.00--3.71-----1.34-1.340.000.52880.00----0.00-99.14---114.72--------------0.00-------61.53------
Kodiak Sciences Inc0.00-232.75m147.62m107.00--0.6119-----4.44-4.440.004.590.00----0.00-43.30-31.73-47.44-33.61------------0.00------21.97--134.76--
I-Mab ADR3.81m-202.01m148.82m220.00--0.6271--39.06-2.43-2.430.04582.930.0083----17,318.04-43.84-35.99-53.14-42.08100.00---5,302.03-496.71---42.630.0171--112.48-12.4641.54---4.66--
Scpharmaceuticals Inc17.63m-57.71m149.27m135.00--6.08--8.47-1.49-1.490.45450.68140.17130.75664.02130,607.40-56.07-38.23-62.13-42.3171.69---327.29-1,360.165.44-16.600.6159-------48.79------
Puma Biotechnology Inc226.63m15.38m150.02m185.009.662.945.570.6620.32190.32194.741.061.1010.958.131,225,016.007.49-12.2111.65-20.5373.4478.786.78-11.791.382.570.6624--3.34-1.251,079,450.00--83.41--
Atossa Therapeutics Inc0.00-29.69m150.91m10.00--1.76-----0.2359-0.23590.000.68330.00----0.00-28.65-29.97-29.84-32.55------------0.00-------11.62---33.90--
Data as of Jun 14 2024. Currency figures normalised to ProQR Therapeutics NV's reporting currency: US Dollar USD

Institutional shareholders

20.22%Per cent of shares held by top holders
HolderShares% Held
Privium Fund Management BVas of 31 Mar 20245.34m6.61%
Adage Capital Management LPas of 31 Mar 20243.63m4.49%
EcoR1 Capital, LLCas of 31 Mar 20242.88m3.57%
M28 Capital Management LPas of 31 Mar 20241.02m1.26%
DAFNA Capital Management LLCas of 31 Mar 2024905.58k1.12%
De Grote Voskuil Capital BVas of 31 Dec 2022740.00k0.92%
Macquarie Investment Management Business Trustas of 31 Mar 2024620.00k0.77%
Ikarian Capital LLCas of 31 Mar 2024483.58k0.60%
DWS Investments (UK) Ltd.as of 31 Mar 2024385.15k0.48%
Millennium Management LLCas of 31 Mar 2024328.99k0.41%
More ▼
Data from 31 Dec 2022 - 31 Mar 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.